


Amendments to the Claims

1. (Currently Amended) A compound according to the formula:




wherein

G is ~~CHC₄-C₆alkyl~~, C=O, CHOH, CF₂, C(OH)CF₃, CHCF₃, C(OH)C₁-C₆alkyl, CH-OC₁-C₆alkyl, CH-O(CO)C₁-C₆alkyl, CHF, CHCN, CHC₂-C₄alkenyl, CHC₂-C₄alkynyl, CHbenzyl, C=CF₂; or 4-(4-hydroxy-phenyl)-2-methylene-1,2,3,3a,4,9b-hexahydro-cyclopenta[c]chromen-8-ol; or a pharmaceutically acceptable salt thereof.

Claims 2-12. (Cancelled)

13. (Previously Presented) A compound according to claim 1 wherein the compound is of the formula:



or a pharmaceutically acceptable salt thereof.

Claims 14 – 37. (Cancelled)






38. (Previously Presented) A pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.







Claims 39 – 41. (Cancelled)







42. (Previously Presented) A method of treating benign prostatic hyperplasia (BPH) in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of Claim 1.






Claims 43 – 47. (Cancelled)

48. (Currently Amended) A compound according to claim 1 selected from the group consisting of:









49. (Previously Presented) A pharmaceutical composition comprising a compound of Claim 13 and a pharmaceutically acceptable carrier.

50. (Previously Presented) A method of treating benign prostatic hyperplasia (BPH) in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of Claim 13.